Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 4 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 3 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2019 Filed Jan 2, 2020 16:22 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 40,000 | $0.38 | $15,340.00 |
DisclosureSEC source: 0001638599-20-000002 · doc4_6445.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,612 F1 · price: Represents the average price of shares purchased at prices that ranged from $0.3821-$0.385. Read SEC document |
| December 10, 2019 Filed Dec 10, 2019 18:00 UTC |
Patel Mahesh V.Director · President and CEO
|
PurchaseCommon Stock | 25,000 | $0.40 | $9,975.00 |
DisclosureSEC source: 0001638599-19-001020 · doc4_6390.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,612 Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 15:42 UTC |
BROWN MORGAN REVP and Chief Financial Office
|
GrantRestricted Stock Unit · Derivative | 70,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,754 Underlying: Common Stock · 70,754 shares Expires 2029-12-05 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit Read SEC document |
| December 05, 2019 Filed Dec 6, 2019 15:42 UTC |
Patel Mahesh V.Director · CEO and President
|
GrantRestricted Stock Unit · Derivative | 122,978 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001010 · doc4_6381.xml · derivative · entry 4 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,978 Underlying: Common Stock · 122,978 shares Expires 2029-12-05 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
BROWN MORGAN REVP and Chief Financial Office
|
Exercise / conversionRestricted Stock Unit · Derivative | 57,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. F5 · derivative.expiration_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
BROWN MORGAN REVP and Chief Financial Office
|
SaleCommon Stock | 17,250 | $0.41 | $7,075.95 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,812 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Represents the weighted average price of shares sold at a price that ranged from $0.4102 - $0.4106. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
BROWN MORGAN REVP and Chief Financial Office
|
Exercise / conversionCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001011 · doc4_6380.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and Chief Financial Office 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
Patel Mahesh V.Director · CEO and President
|
Exercise / conversionRestricted Stock Unit · Derivative | 145,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001010 · doc4_6381.xml · derivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
Patel Mahesh V.Director · CEO and President
|
SaleCommon Stock | 43,500 | $0.41 | $17,835.00 |
DisclosureSEC source: 0001638599-19-001010 · doc4_6381.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,612 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 15:42 UTC |
Patel Mahesh V.Director · CEO and President
|
Exercise / conversionCommon Stock | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-001010 · doc4_6381.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 952,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F2 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 16:14 UTC |
Patel Mahesh V.Director · President and CEO
|
PurchaseCommon Stock | 21,928 | $0.43 | $9,385.18 |
DisclosureSEC source: 0001638599-19-000975 · doc4_6360.xml · nonDerivative · entry 4 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,112 Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 16:14 UTC |
Patel Mahesh V.Director · President and CEO
|
PurchaseCommon Stock | 1,100 | $0.43 | $469.70 |
DisclosureSEC source: 0001638599-19-000975 · doc4_6360.xml · nonDerivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,184 Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 16:14 UTC |
Patel Mahesh V.Director · President and CEO
|
PurchaseCommon Stock | 700 | $0.43 | $298.62 |
DisclosureSEC source: 0001638599-19-000975 · doc4_6360.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,084 Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 16:14 UTC |
Patel Mahesh V.Director · President and CEO
|
PurchaseCommon Stock | 1,272 | $0.43 | $542.51 |
DisclosureSEC source: 0001638599-19-000975 · doc4_6360.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,384 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:18 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 4,810 | $0.42 | $2,019.24 |
DisclosureSEC source: 0001638599-19-000966 · doc4_6352.xml · nonDerivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,112 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:18 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 40,259 | $0.40 | $16,103.60 |
DisclosureSEC source: 0001638599-19-000966 · doc4_6352.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,302 Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:18 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 4,931 | $0.40 | $1,971.91 |
DisclosureSEC source: 0001638599-19-000966 · doc4_6352.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,043 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 11:10 UTC |
HILL STEPHEN ADirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000610 · doc4_6152.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:10 UTC |
Ono Richard DanaDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000609 · doc4_6153.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:11 UTC |
Higuchi John W.Director
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000611 · doc4_6151.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:10 UTC |
Fink Jeffrey ArvinDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000608 · doc4_6154.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| May 24, 2019 Filed May 28, 2019 14:54 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantCommon Stock | 2,500 | $1.64 | $4,100.00 |
DisclosureSEC source: 0001638599-19-000557 · doc4_6127.xml · nonDerivative · entry 4 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,112 Read SEC document |
| May 24, 2019 Filed May 28, 2019 14:54 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantCommon Stock | 473 | $1.60 | $756.80 |
DisclosureSEC source: 0001638599-19-000557 · doc4_6127.xml · nonDerivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,612 Read SEC document |
| May 24, 2019 Filed May 28, 2019 14:54 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantCommon Stock | 2,500 | $1.59 | $3,975.00 |
DisclosureSEC source: 0001638599-19-000557 · doc4_6127.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,139 Read SEC document |
| May 24, 2019 Filed May 28, 2019 14:54 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantCommon Stock | 4,527 | $1.58 | $7,152.66 |
DisclosureSEC source: 0001638599-19-000557 · doc4_6127.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,639 Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC |
BROWN MORGAN REVP and CFO
|
GrantStock Option (Right to buy) · Derivative | 75,000 | $1.46 Strike: $1.46 | $109,500.00 |
DisclosureSEC source: 0001638599-18-001326 · doc4_5816.xml · derivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-12-04 F3 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC |
BROWN MORGAN REVP and CFO
|
GrantRestricted Stock Unit · Derivative | 115,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-001326 · doc4_5816.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2028-12-04 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $1.46 Strike: $1.46 | $219,000.00 |
DisclosureSEC source: 0001638599-18-001327 · doc4_5817.xml · derivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-12-04 F3 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC |
Patel Mahesh V.Director · President and CEO
|
GrantRestricted stock unit · Derivative | 290,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-001327 · doc4_5817.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2028-12-04 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 12:28 UTC |
HILL STEPHEN ADirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000697 · doc4_5499.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:29 UTC |
Fink Jeffrey ArvinDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000700 · doc4_5502.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:29 UTC |
Ono Richard DanaDirector
|
GrantStcck Optoin (right to buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000699 · doc4_5501.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:28 UTC |
Higuchi John W.Director
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000698 · doc4_5500.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
BROWN MORGAN REVP and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common stock · 9,375 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
BROWN MORGAN REVP and CFO
|
SaleCommon stock | 2,813 | $3.47 | $9,773.49 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,562 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
BROWN MORGAN REVP and CFO
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000028 · doc4_5172.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC |
HILL STEPHEN ADirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · derivative · entry 3 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common stock · 2,500 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC |
HILL STEPHEN ADirector
|
SaleCommon stock | 1,250 | $3.47 | $4,341.50 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · nonDerivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 18:15 UTC |
HILL STEPHEN ADirector
|
Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000027 · doc4_5173.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Bass Gregory BrooksChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000030 · doc4_5170.xml · derivative · entry 3 Bass Gregory Brooks · CIK 0001696824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common stock · 9,375 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Bass Gregory BrooksChief Commercial Officer
|
SaleCommon stock | 3,750 | $3.47 | $13,023.38 |
DisclosureSEC source: 0001638599-18-000030 · doc4_5170.xml · nonDerivative · entry 2 Bass Gregory Brooks · CIK 0001696824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Bass Gregory BrooksChief Commercial Officer
|
Exercise / conversionCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000030 · doc4_5170.xml · nonDerivative · entry 1 Bass Gregory Brooks · CIK 0001696824 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Patel Mahesh V.Director · CEO, President
|
Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · derivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 15,000 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Patel Mahesh V.Director · CEO, President
|
SaleCommon stock | 6,000 | $3.48 | $20,866.80 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,112 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.55. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC |
Patel Mahesh V.Director · CEO, President
|
Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
Ono Richard DanaDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · derivative · entry 3 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common stock · 1,750 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
Ono Richard DanaDirector
|
SaleCommon stock | 875 | $3.47 | $3,033.36 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · nonDerivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
Ono Richard DanaDirector
|
Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000026 · doc4_5174.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
Higuchi John W.Director
|
Exercise / conversionRestricted stock units · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000025 · doc4_5176.xml · derivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1.25 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:15 UTC |
Higuchi John W.Director
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000025 · doc4_5176.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 2). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.